All ‘ablate and pace’ patients with heart failure and atrial fibrillation should be offered physiological pacing regardless of left ventricular function: pro

27 August 2023 (09:15 - 09:30)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Marek Jastrzebski

Jagiellonian University, Krakow (Poland)

5 More presentations in this session

Presentation thumbnail

First-line atrial fibrillation ablation should be offered to all patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF): pro

Professor N. Marrouche (New Orleans, US)

Presentation thumbnail

First-line atrial fibrillation ablation should be offered to all patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF): con

Professor I. Van Gelder (Groningen, NL)

Presentation thumbnail

First-line atrial fibrillation ablation should be offered to all patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) - discussion

Presentation thumbnail

All ‘ablate and pace’ patients with heart failure and atrial fibrillation should be offered physiological pacing regardless of left ventricular function: con

Professor J. Cleland (Glasgow, GB)

Presentation thumbnail

All ‘ablate and pace’ patients with heart failure and atrial fibrillation should be offered physiological pacing regardless of left ventricular function - discussion

Access the full session

Session thumbnail

Great Debate: how to manage patients with heart failure and atrial fibrillation

The Event

Event poster

ESC Congress 2023

27 August 2023 09:15 CET

You may be interested in

Congress Presentation

Acute cardiovascular disease in patients with active cancer: what every cardiologist should know - discussion

Congress Presentation

First-line atrial fibrillation ablation should be offered to all patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF): pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources